EGFR and non-small cell lung carcinoma: Initial observations indicated that being the EGFR-TKIs substrates of ATP-binding cassette transporters, such as P-glycoprotein (Pgp), they could be utilized as a synergistic strategy for antagonizing Pgp-mediated resistance to chemotherapeutic drugs in NSCLC cells not harboring sensitizing EGFR-mutations [255,256].